FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3164864665> ?p ?o ?g. }

• W3164864665 endingPage "e409" @default.
• W3164864665 startingPage "e398" @default.
• W3164864665 abstract "Background The German Hodgkin Study Group's HD18 trial established the safety and efficacy of PET-guided eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses) for the treatment of advanced-stage Hodgkin lymphoma. However, because of a protocol amendment during the enrolment period (June 1, 2011) that changed standard treatment from eight to six cycles, the results of the HD18 trial have been partially immature. We report a prespecified 5-year follow-up analysis of the completed HD18 trial. Methods HD18 was an international, open-label, randomised, phase 3 trial done in 301 hospitals and private practices in five European countries. Patients aged 18–60 years with newly diagnosed, advanced-stage Hodgkin lymphoma and an Eastern Cooperative Oncology Group performance status of 0–2 were recruited. After receiving an initial two cycles of eBEACOPP (1250 mg/m2 intravenous cyclophosphamide [day 1], 35 mg/m2 intravenous doxorubicin [day 1], 200 mg/m2 intravenous etoposide [day 1–3], 100 mg/m2 oral procarbazine [day 1–7], 40 mg/m2 oral prednisone [day 1–14], 1·4 mg/m2 intravenous vincristine [day 8], and 10 mg/m2 intravenous bleomycin [day 8]), patients underwent a contrast-enhanced CT and PET scan (PET-2). Patients with positive PET-2 were randomly assigned to receive standard therapy (an additional six cycles of eBEACOPP; ie, eight cycles in total) or experimental therapy (an additional six cycles of eBEACOPP plus 375 mg/m2 intravenous rituximab; ie, eight cycles in total) until June 1, 2011. After June 1, 2011, all patients with positive PET-2 were assigned to the updated standard therapy with an additional four cycles of eBEACOPP (ie, six cycles in total). Patients with negative PET-2 were randomly assigned (1:1) to receive standard therapy (an additional six cycles of eBEACOPP [ie, eight cycles in total] until June 1, 2011; an additional four cycles of eBEACOPP [ie, six cycles in total] after June 1, 2011) or experimental therapy (an additional two cycles of eBEACOPP; ie, four cycles in total). Randomisation was done centrally with the minimisation method, including a random component, stratified by centre, age, stage, international prognostic score, and sex. The primary endpoint was progression-free survival. HD18 aimed to improve 5-year progression-free survival by 15% in the PET-2-positive intention-to-treat cohort and to exclude inferiority of 6% or more in 5-year progression-free survival in the PET-2-negative per-protocol population. This study is registered with ClinicalTrials.gov, NCT00515554, and is completed. Findings Between May 14, 2008, and July 18, 2014, 2101 patients were enrolled and 1945 were assigned to a treatment group according to their PET-2 result. In the PET-2-positive cohort, with a median follow-up of 73 months (IQR 59 to 94), 5-year progression-free survival was 89·9% (95% CI 85·7 to 94·1) in 217 patients assigned to eight cycles of eBEACOPP before the protocol amendment and 87·7% (83·1 to 92·4) in 217 patients assigned to eight cycles of rituximab plus eBEACOPP (p=0·40). Among 506 patients who received six cycles of eBEACOPP after the protocol amendment, 5-year progression-free survival was 90·1% (95% CI 87·2 to 92·9), with a median follow-up of 58 months (IQR 39 to 66). In the PET-2-negative cohort, with a median follow-up of 66 months (IQR 54 to 85) in the combined pre-amendment and post-amendment groups, 5-year progression-free survival was 91·2% (95% CI 88·4 to 93·9) in 446 patients who received eight or six cycles of eBEACOPP and 93·0% (90·6 to 95·4) in 474 patients who received four cycles of eBEACOPP (difference 1·9% [95% CI −1·8 to 5·5]). In the subgroup of PET-2-negative patients randomly assigned after protocol amendment, 5-year progression-free survival was 90·9% (95% CI 86·8 to 95·1) in 202 patients assigned to receive six cycles of eBEACOPP and 91·0% (86·6 to 95·5) in 200 patients assigned to receive four cycles of eBEACOPP (difference 0·1% [–5·9 to 6·2]). Interpretation Long-term follow-up confirms the efficacy and safety of PET-2-guided eBEACOPP in patients with advanced-stage Hodgkin lymphoma. The reduction from eight to four cycles of eBEACOPP represents a benchmark in the treatment of early-responding patients, who can now be potentially cured with a short and safe treatment approach. Funding Deutsche Krebshilfe, Swiss State Secretariat for Education, Research and Innovation SERI (Switzerland), and Roche Pharma. Translation For the German translation of the abstract see Supplementary Materials section." @default.
• W3164864665 created "2021-06-07" @default.
• W3164864665 creator A5000334325 @default.
• W3164864665 creator A5003056562 @default.
• W3164864665 creator A5003363227 @default.
• W3164864665 creator A5008778599 @default.
• W3164864665 creator A5016787940 @default.
• W3164864665 creator A5019792751 @default.
• W3164864665 creator A5019862530 @default.
• W3164864665 creator A5020097248 @default.
• W3164864665 creator A5025613660 @default.
• W3164864665 creator A5028510513 @default.
• W3164864665 creator A5039994927 @default.
• W3164864665 creator A5041565323 @default.
• W3164864665 creator A5043426460 @default.
• W3164864665 creator A5046794427 @default.
• W3164864665 creator A5047674033 @default.
• W3164864665 creator A5053252307 @default.
• W3164864665 creator A5055422099 @default.
• W3164864665 creator A5055488306 @default.
• W3164864665 creator A5057387418 @default.
• W3164864665 creator A5064132655 @default.
• W3164864665 creator A5064401286 @default.
• W3164864665 creator A5065162388 @default.
• W3164864665 creator A5065655150 @default.
• W3164864665 creator A5068013617 @default.
• W3164864665 creator A5071272497 @default.
• W3164864665 creator A5071753657 @default.
• W3164864665 creator A5075117420 @default.
• W3164864665 creator A5076460303 @default.
• W3164864665 creator A5078376583 @default.
• W3164864665 creator A5081642625 @default.
• W3164864665 creator A5083161940 @default.
• W3164864665 creator A5086766354 @default.
• W3164864665 creator A5087670472 @default.
• W3164864665 creator A5089318791 @default.
• W3164864665 date "2021-06-01" @default.
• W3164864665 modified "2023-10-18" @default.
• W3164864665 title "PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial" @default.
• W3164864665 cites W1905050374 @default.
• W3164864665 cites W1973535185 @default.
• W3164864665 cites W2010746974 @default.
• W3164864665 cites W2034526812 @default.
• W3164864665 cites W2047008293 @default.
• W3164864665 cites W2078016415 @default.
• W3164864665 cites W2101873015 @default.
• W3164864665 cites W2107069243 @default.
• W3164864665 cites W2118169390 @default.
• W3164864665 cites W2131853861 @default.
• W3164864665 cites W2133487516 @default.
• W3164864665 cites W2147033265 @default.
• W3164864665 cites W2158830277 @default.
• W3164864665 cites W2338057729 @default.
• W3164864665 cites W2342440786 @default.
• W3164864665 cites W2469052042 @default.
• W3164864665 cites W2515183449 @default.
• W3164864665 cites W2591215304 @default.
• W3164864665 cites W2756060398 @default.
• W3164864665 cites W2765462510 @default.
• W3164864665 cites W2767770931 @default.
• W3164864665 cites W2775803967 @default.
• W3164864665 cites W2779638234 @default.
• W3164864665 cites W2895148735 @default.
• W3164864665 cites W2902301096 @default.
• W3164864665 cites W2954226397 @default.
• W3164864665 cites W3036192372 @default.
• W3164864665 doi "https://doi.org/10.1016/s2352-3026(21)00101-0" @default.
• W3164864665 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34048679" @default.
• W3164864665 hasPublicationYear "2021" @default.
• W3164864665 type Work @default.
• W3164864665 sameAs 3164864665 @default.
• W3164864665 citedByCount "25" @default.
• W3164864665 countsByYear W31648646652021 @default.
• W3164864665 countsByYear W31648646652022 @default.
• W3164864665 countsByYear W31648646652023 @default.
• W3164864665 crossrefType "journal-article" @default.
• W3164864665 hasAuthorship W3164864665A5000334325 @default.
• W3164864665 hasAuthorship W3164864665A5003056562 @default.
• W3164864665 hasAuthorship W3164864665A5003363227 @default.
• W3164864665 hasAuthorship W3164864665A5008778599 @default.
• W3164864665 hasAuthorship W3164864665A5016787940 @default.
• W3164864665 hasAuthorship W3164864665A5019792751 @default.
• W3164864665 hasAuthorship W3164864665A5019862530 @default.
• W3164864665 hasAuthorship W3164864665A5020097248 @default.
• W3164864665 hasAuthorship W3164864665A5025613660 @default.
• W3164864665 hasAuthorship W3164864665A5028510513 @default.
• W3164864665 hasAuthorship W3164864665A5039994927 @default.
• W3164864665 hasAuthorship W3164864665A5041565323 @default.
• W3164864665 hasAuthorship W3164864665A5043426460 @default.
• W3164864665 hasAuthorship W3164864665A5046794427 @default.
• W3164864665 hasAuthorship W3164864665A5047674033 @default.
• W3164864665 hasAuthorship W3164864665A5053252307 @default.
• W3164864665 hasAuthorship W3164864665A5055422099 @default.
• W3164864665 hasAuthorship W3164864665A5055488306 @default.
• W3164864665 hasAuthorship W3164864665A5057387418 @default.
• W3164864665 hasAuthorship W3164864665A5064132655 @default.
• W3164864665 hasAuthorship W3164864665A5064401286 @default.
• W3164864665 hasAuthorship W3164864665A5065162388 @default.

• next